{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T05:08:23Z","timestamp":1763788103828,"version":"3.45.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.clinthera.2025.06.016","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T11:14:52Z","timestamp":1754565292000},"page":"691-695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pegylated Liposomal Doxorubicin Confers a High Risk for Pneumocystis Jirovecii Pneumonia in Patients With Diffuse Large B-Cell Lymphoma"],"prefix":"10.1016","volume":"47","author":[{"suffix":"MD","given":"Siqian","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"MD","given":"Yongyong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanhu","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyuan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"MD","given":"Lan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"MD","given":"Haige","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honglan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songfu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3809-7613","authenticated-orcid":false,"suffix":"MD","given":"Shujuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.06.016_bib0001","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0002","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0003","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clml.2014.09.001","article-title":"Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial","volume":"15","author":"Oki","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0004","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/CAD.0000000000000037","article-title":"Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer","volume":"25","author":"Rom","year":"2014","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0005","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0006","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1080\/10428190600799946","article-title":"CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma","volume":"47","author":"Zaja","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0007","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1634\/theoncologist.11-6-666","article-title":"Liposomal doxorubicin, cyclophosphamide, and etoposide and antiretroviral therapy for patients with AIDS-related lymphoma: a pilot study","volume":"11","author":"Combs","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0008","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.3109\/10428194.2015.1029925","article-title":"Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study","volume":"56","author":"Iannitto","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0009","first-page":"7","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0010","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1378\/chest.12-0477","article-title":"Pneumocystis pneumonia in patients treated with rituximab","volume":"144","author":"Martin-Garrido","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0011","first-page":"E162","article-title":"Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma after Rituximab-containing regimen: two cases of report and literature review","volume":"5","author":"Jiang","year":"2013","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0012","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1600-0609.2007.00994.x","article-title":"Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma","volume":"80","author":"Venhuizen","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0013","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dkw158","article-title":"ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients","volume":"71","author":"Maschmeyer","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0014","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1378\/chest.118.3.704","article-title":"Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states","volume":"118","author":"Mansharamani","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0015","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3109\/10428191003699860","article-title":"High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone","volume":"51","author":"Kamel","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0016","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/myc.13184","article-title":"Pneumocystis jirovecii pneumonia in diffuse large B-cell Lymphoma treated with R-CHOP","volume":"64","author":"Lee","year":"2021","journal-title":"Mycoses"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0017","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.clml.2011.06.011","article-title":"Interstitial pneumonia after autologous hematopoietic stem cell transplantation in B-cell non-hodgkin lymphoma","volume":"11","author":"Kato","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0018","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0019","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0020","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0021","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0022","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0023","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1080\/1120009X.2021.1920248","article-title":"Pegylated liposomal doxorubicin as first line treatment in aids-related Kaposi's sarcoma: a real-life study","volume":"33","author":"Dalu","year":"2021","journal-title":"J Chemother"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0024","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3109\/10428194.2010.525726","volume":"52","author":"Isidori","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0025","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00277-017-3160-1","article-title":"Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab","volume":"97","author":"Zhou","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0026","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hon.2425","article-title":"Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi","volume":"36","author":"Luminari","year":"2018","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0027","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s12185-008-0066-7","article-title":"Increased incidence of interstitial pneumonia by CHOP combined with rituximab","volume":"87","author":"Ennishi","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0028","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s12032-011-9893-0","article-title":"Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer","volume":"29","author":"Inaba","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0029","article-title":"Pulmonary fibrosis after pegylated liposomal doxorubicin in elderly patient with cutaneous angiosarcoma","volume":"2016","author":"Mazzotta","year":"2016","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0030","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/039463200601900202","article-title":"Role of pegylated lyposomal doxorubicin (PLD) in systemic Kaposi's sarcoma: a systematic review","volume":"19","author":"Di Trolio","year":"2006","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0031","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00003246-200103000-00013","article-title":"The importance of bacterial sepsis in intensive care unit patients with acquired immunodeficiency syndrome: implications for future care in the age of increasing antiretroviral resistance","volume":"29","author":"Rosenberg","year":"2001","journal-title":"Crit Care Med"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0032","article-title":"Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: a Systemic Review and Meta-Analysis","volume":"10","author":"Jiang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0033","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1007\/s00277-023-05303-5","article-title":"Trimethoprim-sulfamethoxazole prevents interstitial pneumonitis in B-cell lymphoma patients receiving chemotherapy: a propensity score matching analysis","volume":"102","author":"Liu","year":"2023","journal-title":"Ann Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2025.06.016_bib0034","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/427295","article-title":"Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America","volume":"40","author":"Mofenson","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0035","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3816\/CLM.2006.n.019","article-title":"Fatal interstitial pneumonitis related to rituximab-containing regimen","volume":"6","author":"Herishanu","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0036","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3960\/jslrt.50.159","article-title":"Two cases of Pneumocystis jiroveci pneumonia with non-Hodgkin's lymphoma after CHOP-based chemotherapy containing rituximab","volume":"50","author":"Kurokawa","year":"2010","journal-title":"J Clin Exp Hematop"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0037","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4065\/82.9.1052","article-title":"Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials","volume":"82","author":"Green","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0038","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199503163321101","article-title":"A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group","volume":"332","author":"Bozzette","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.06.016_bib0039","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00042560-199706010-00002","article-title":"Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients","volume":"15","author":"Bucher","year":"1997","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T05:03:40Z","timestamp":1763787820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825002334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0149291825002334"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.06.016","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pegylated Liposomal Doxorubicin Confers a High Risk for Pneumocystis Jirovecii Pneumonia in Patients With Diffuse Large B-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}